BioRay`s BR111 ADC Gets NMPA Clinical Trial Approval
10 Feb 2025 //
PR NEWSWIRE
BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812
07 Nov 2023 //
PR NEWSWIRE
Trial Application (IND) for BioRay`s BR105 Injection Receives U.S. FDA Approval
24 Oct 2023 //
PR NEWSWIRE
Zuberitamab (Anruixi®) has been approved for marketing in China
13 Sep 2023 //
PR NEWSWIRE
BioRay Filed IND for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1
24 May 2023 //
PR NEWSWIRE